Search Results

FDA Approves Novel Car T-Immunotherapy for the Treatment of Multiple Myeloma

LLS makes progress for blood cancer patients through virtual advocacy

Meetings with lawmakers, testimonies at state legislatures, and events with passionate volunteers are all staples of advocacy. Historically, those are some of the ways we accomplish that work. But COVID-19 prompted us to rethink the way our staff and volunteers share their message with lawmakers.

Digital Resources

In addition to our programs and services for blood cancer patients, families and caregivers, The Leukemia & Lymphoma Society (LLS) is pleased to offer an extensive directory of national and international resources. It may be helpful for you to browse each section to discover all that's offered.

Blood Cancer - General Information

Blood Cancer Treatment

Health Insurance - US

Patient Well-Being During Treatment

Professional Organizations for Health Care Providers

Related Diseases and Conditions

Resources - Canada and International

Patient and Caregiver Support and Counseling

Understanding Myeloma: A Quick Guide

Myeloma is a rare blood cancer

Stronger Together: Navigating Cancer as Newlyweds

As we round out our first year of marriage and our first year of battling cancer, I recently asked my husband Brad how he would describe this past year. “Disrupted.” Before cancer, we had plans: big, extravagant, travel-the-world kind of plans. After two years of a long-distance relationship, we were finally going to live in the same city. We were going to get settled in our brand-new home. We were going to make new Florida friends. We were excited about the opportunities we had in our careers. We were going to capitalize on the “newlywed phase” to the fullest extent!

Fertility and Pregnancy

In addition to our programs and services for blood cancer patients, families and caregivers, The Leukemia & Lymphoma Society (LLS) is pleased to offer an extensive directory of national and international resources. These organizations can help with cancer-related issues like financial assistance, support and counseling, assistance with transportation, and summer camps.

Advocates standing alongside NJ governor for the medical debt bill signing ceremony

LLS teams up with advocates to advance policies that protect patients from medical debt

Financial Resources

For information about LLS's financial assistance programs, click here.

Other Helpful Organizations

In addition to our programs and services for blood cancer patients, families and caregivers, LLS is pleased to offer an extensive directory of national and international resources. These organizations can help with cancer-related issues like financial assistance, support and counseling, assistance with transportation, etc. It may be helpful for you to browse through each section to discover all that is offered.

Support Groups

Reach Out to Others for Support

The Leukemia & Lymphoma Society's (LLS's) support groups are the perfect place to talk with other people affected by blood cancers, including patients, family members and caregivers. The groups provide mutual support and offer the opportunity to discuss anxieties and concerns with others who share the same experiences. This sharing strengthens the family bond and enhances everyone's ability to cope with cancer.

Myeloma cell and model of human skeleton

Champions in myeloma research, Part 2: A conversation with Suzanne Lentzsch, M.D., Ph.D.

To commemorate both Myeloma Awareness Month and Women’s History Month during March, I’ve been talking with LLS-funded women scientists who are driving discovery for myeloma patients. As we close out the month and my two-part series on myeloma researchers, I’m excited to share my recent conversation with Suzanne Lentzsch, M.D., Ph.D., Professor of Medicine and the Director of the Multiple Myeloma and Amyloidosis Program at Columbia University.

Assistance with Finding Low-Cost Prescriptions

Please note that these resources are regularly reviewed to ensure that links still work correctly and that the resources listed continue to be helpful to our visitors. If you find that a link isn't working or information is incorrect, please email infocenter@lls.org. If you would like for us to consider adding your organization to this resource, please complete and submit this form.

Cellular Crosstalk In The Normal And Malignant Bone Marrow

We want to understand how leukemia inhibits blood production as this is one of the main causes of death in leukemia patients. We use new microscopy techniques developed by our group to image—for the first time—all types of blood cells and how they are eradicated by leukemia cells. Identification of the mechanisms through which leukemia inhibits blood production will be the foundation for new studies to develop drugs to maintain normal blood levels and prevent death in leukemia patients.

Optimizing MICA/B antibody for AML by selective binding to Fc activating receptors

Acute myeloid leukemia (AML) is a blood cancer characterized by poor clinical outcomes. We developed an antibody that inhibits AML in models by triggering anti-leukemia immunity. Now we developed a new version of this antibody with higher affinity to the leukocyte receptors that mediate anti-leukemia immunity. We will establish the ability of this optimized antibody to elicit greater inhibition of AML. The studies will generate important information about how to induce anti-leukemia immunity.

close up, two people holding hands, sitting on a couch

Lymphoma diagnosis, survival rate by age, prognosis, and treatment

Table of contents:

LLS ANSWERS 10 QUESTIONS ABOUT COVID-19 VACCINES

Investigating the impact of hotspot mutations in a chromatin reader on leukemogenesis

The goal of this proposal is to investigate the consequence of the chromatin reader eleven-nineteen-leukemia (ENL) gain-of-function mutations in the pathogenesis of leukemia. Our studies leverage the expertise in the molecular and chromatin biology of chromatin reader in leukemia utilizing mouse model, high resolution image, epigenomic and transcriptomic approaches. Our goal is to understand how chromatin reader contributes to cancer development, progression, and therapeutic outcome.